Physician profile
James J Boylan
NPI 1538159546
$5,933.45
in general payments reported to CMS, 2019-2025
41 companies · $1,500 in 2025
The $1,500 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,006 · 2020: $37.26 · 2021: $529 · 2022: $858 · 2023: $671 · 2024: $1,332 · 2025: $1,500.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,455 · Education: $47.98.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,454.75 |
| Education | $47.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,003.69 | 2019-2025 | Tremfya, Stelara, Remicade |
| Abbvie INC. | $929.04 | 2019-2025 | Rinvoq |
| Takeda Pharmaceuticals U.S.A., INC. | $561.22 | 2019-2025 | Entyvio, Ninlaro |
| E.R. Squibb & Sons, L.L.C. | $474.12 | 2021-2024 | Zeposia, Opdivo |
| Daiichi Sankyo INC. | $386.13 | 2022-2025 | Injectafer, Datroway, Enhertu |
| Pfizer INC. | $351.31 | 2019-2025 | |
| Celltrion USA INC. | $182.41 | 2023-2024 | Vegzelma, Zymfentra |
| Madrigal Pharmaceuticals | $180.66 | 2025 | Rezdiffra |
| Qol Medical, LLC | $169.33 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $142.74 | 2021-2022 | |
| Incyte Corporation | $138.87 | 2021-2025 | Jakafi, Monjuvi, Pemazyre |
| Celgene Corporation | $137.46 | 2021-2024 | Zeposia |
| Organon LLC | $126.35 | 2023-2024 | Hadlima, Renflexis |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $117.50 | 2021-2025 | Xifaxan |
| Janssen Scientific Affairs, LLC | $88.49 | 2019 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Boylan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.